Updates in Systemic Lupus Erythematosus
Unlocking Novel Paths to Patient Care
Meeting Slides
Classification Criteria
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.
Aringer M, et al. Arthritis Rheumatol. 2019;71(9):1400-1412.
Disease Management Guidelines
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Fanouriakis A, et al. Ann Rheum Dis. 2019;78(6):736-745.
Patient Resources
American College of Rheumatology
Lupus Foundation of America
Lupus Research Alliance
Disease Activity Indices
Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties.
Chessa E, et al. Rheumatology (Oxford). 2020;59(12):3622-3632.
Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study.
Golder V, et al. Lancet Rheumatol. 2019;1(2):e95-e102.
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus.
Isenberg DA, et al. Rheumatology (Oxford). 2005;44(7):902-906.
Development and initial validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50.
Touma Z, et al. J Rheumatol. 2011;38(2):275-284.
Suggested Readings
European League Against Rheumatism (EULAR) 2020 Annual Meeting Abstracts.
June 3-6, 2020. Virtual.
American College of Rheumatology (ACR) Annual Meeting Abstracts.
November 5-9, 2020. Virtual.
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
van Vollenhoven RF, et al. Ann Rheum Dis. 2014;73(6):958-967.
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
Furie RA, et al. Lancet Rheumatol. 2019;1(4):e208-e219.
Trial of anifrolumab in active systemic lupus erythematosus.
Morand EF, et al. N Engl J Med. 2020;382(3):211-221.
Anifrolumab, an anti–interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.
Furie R, et al. Arthritis Rheumatol. 2017;69(2):376-386.
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R, et al. Arthritis Rheum. 2011;63(12):3918-3930.
Two-year, randomized, controlled trial of belimumab in lupus nephritis.
Furie R, et al. N Engl J Med. 2020;383(12):1117-1128.
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.
Morand EF, et al. Ann Rheum Dis. 2018;77(5):706-713.
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV, et al. Lancet. 2011;377(9767):721-731.
AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis.
Arriens C, et al. Ann Rheum Dis. 2020;79(suppl 1):172-173.
B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis.
Furie R, et al. Lupus Sci Med. 2020;7(suppl 1):A27-A28.
Comprehensive efficacy of anifrolumab across organ domains in patients with active SLE: pooled data from 2 phase 3 trials.
Morand E, et al. Arthritis Rheumatol. 2020;72(suppl 10).
Flare reduction and oral corticosteroid taper in patients with active SLE treated with anifrolumab in 2 phase 3 trials.
Furie R, et al. Arthritis Rheumatol. 2020;72(suppl 10).
Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis.
Furie R, et al. Arthritis Rheumatol. 2020;72(suppl 10).
Interactive PresentationImmunopathogenesis of SLE
This short 3D animation reviews the immunopathogenesis of systemic lupus erythematosus (SLE), relevant disease pathophysiology, and newer targeted therapies.
Unlocking Novel Paths to Patient Care
Unlocking Novel Paths to Patient Care
Unlocking Novel Paths to Patient Care
Relevant Resources
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Debates & Discussions on the Evolving Role of JAK Inhibitors
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
New Avenues to the Management of Severe Asthma
Interdisciplinary Strategies for Adult and Pediatric Patients
